Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

December 5, 2024

Study Completion Date

December 31, 2026

Conditions

Peripheral Arterial Disease

Interventions

DEVICE

Standard stenting

The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.

Trial Locations (5)

Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu

Saiseikai Fukuoka General Hospital, Fukuoka

Kokura Memorial Hospital, Kitakyushu

Shonan Kamakura General Hospital, Kamakura

Osaka Keisatsu Hospital, Osaka City, Osaka

All Listed Sponsors

lead

Otsuka Medical Devices Co., Ltd. Japan

INDUSTRY